Modality.AI helps pharmaceutical companies increase the efficiency of clinical trials for therapies of neurological and mental conditions by providing a portfolio of rich audio-visual biomarkers.

Modality's proprietary and field-tested platform engages subjects in naturalistic spoken interaction and analyzes their speech responses and facial behaviors, providing objective measures that have been shown to strongly correlate with the clinical outcome.

Applications for ALS, Autism, depression, and anxiety have been created using the Modality platform. Protocols spanning other conditions such as Alzheimer's disease and post-stroke impairment are being developed.

Modality's core technology was developed in collaboration with UCSF, UT Southwestern Medical Center, and Massachusetts General, and is being used in IRB-approved clinical studies.

. . .